(firstQuint)To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD.

 This was a multicenter, open-label, randomized, active controlled, parallel group chronic safety study of arformoterol 50 mcg once daily over a period of 12 months in subjects with COPD.

 This study was previously posted by Sepracor Inc.

 In October 2009, Sepracor Inc.

 was acquired by Dainippon Sumitomo Pharma.

, and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

.

 To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD@highlight

The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD